Logo image of AEMD

AETHLON MEDICAL INC (AEMD) Stock Fundamental Analysis

NASDAQ:AEMD - Nasdaq - US00808Y4061 - Common Stock - Currency: USD

0.3753  0 (-1.24%)

After market: 0.3561 -0.02 (-5.12%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AEMD. AEMD was compared to 191 industry peers in the Health Care Equipment & Supplies industry. While AEMD seems to be doing ok healthwise, there are quite some concerns on its profitability. AEMD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AEMD had negative earnings in the past year.
In the past year AEMD has reported a negative cash flow from operations.
In the past 5 years AEMD always reported negative net income.
AEMD had a negative operating cash flow in each of the past 5 years.
AEMD Yearly Net Income VS EBIT VS OCF VS FCFAEMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

AEMD has a worse Return On Assets (-127.38%) than 85.86% of its industry peers.
With a Return On Equity value of -187.24%, AEMD is not doing good in the industry: 73.30% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -127.38%
ROE -187.24%
ROIC N/A
ROA(3y)-90.16%
ROA(5y)-81.14%
ROE(3y)-117.5%
ROE(5y)-100.77%
ROIC(3y)N/A
ROIC(5y)N/A
AEMD Yearly ROA, ROE, ROICAEMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

AEMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AEMD Yearly Profit, Operating, Gross MarginsAEMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

AEMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
AEMD has more shares outstanding than it did 1 year ago.
AEMD has more shares outstanding than it did 5 years ago.
AEMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AEMD Yearly Shares OutstandingAEMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
AEMD Yearly Total Debt VS Total AssetsAEMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -27.31, we must say that AEMD is in the distress zone and has some risk of bankruptcy.
AEMD has a worse Altman-Z score (-27.31) than 87.96% of its industry peers.
AEMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.31
ROIC/WACCN/A
WACC9.16%
AEMD Yearly LT Debt VS Equity VS FCFAEMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M 15M

2.3 Liquidity

AEMD has a Current Ratio of 3.06. This indicates that AEMD is financially healthy and has no problem in meeting its short term obligations.
AEMD's Current ratio of 3.06 is in line compared to the rest of the industry. AEMD outperforms 57.59% of its industry peers.
AEMD has a Quick Ratio of 3.06. This indicates that AEMD is financially healthy and has no problem in meeting its short term obligations.
AEMD's Quick ratio of 3.06 is fine compared to the rest of the industry. AEMD outperforms 66.49% of its industry peers.
Industry RankSector Rank
Current Ratio 3.06
Quick Ratio 3.06
AEMD Yearly Current Assets VS Current LiabilitesAEMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.34% over the past year.
The Revenue for AEMD has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)68.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.51%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AEMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.77% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y84.91%
EPS Next 2Y37.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AEMD Yearly Revenue VS EstimatesAEMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
AEMD Yearly EPS VS EstimatesAEMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AEMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AEMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AEMD Price Earnings VS Forward Price EarningsAEMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AEMD Per share dataAEMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as AEMD's earnings are expected to grow with 37.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.77%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AEMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AETHLON MEDICAL INC

NASDAQ:AEMD (4/24/2025, 8:00:00 PM)

After market: 0.3561 -0.02 (-5.12%)

0.3753

0 (-1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12 2025-02-12/amc
Earnings (Next)06-25 2025-06-25/amc
Inst Owners11.04%
Inst Owner Change0%
Ins Owners0.44%
Ins Owner Change-2.6%
Market Cap7.75M
Analysts80
Price Target3.95 (952.49%)
Short Float %3.33%
Short Ratio0.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3.19%
Min EPS beat(2)-5.82%
Max EPS beat(2)-0.55%
EPS beat(4)1
Avg EPS beat(4)2.97%
Min EPS beat(4)-9.2%
Max EPS beat(4)27.47%
EPS beat(8)3
Avg EPS beat(8)-0.2%
EPS beat(12)5
Avg EPS beat(12)-5.92%
EPS beat(16)7
Avg EPS beat(16)-4.39%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)15.7%
EPS NY rev (3m)26.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 1.29
EV/EBITDA N/A
EPS(TTM)-1.58
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0
BVpS0.29
TBVpS0.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -127.38%
ROE -187.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.16%
ROA(5y)-81.14%
ROE(3y)-117.5%
ROE(5y)-100.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.11%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.06
Quick Ratio 3.06
Altman-Z -27.31
F-Score2
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)251.07%
Cap/Depr(5y)280.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.51%
EPS Next Y84.91%
EPS Next 2Y37.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y28.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.12%
OCF growth 3YN/A
OCF growth 5YN/A